Bull&Bear | Mixed Fortunes: TTEC and CRVO Soar, NMAX and WTF Dive

**Stock Performers: Bull Market**

TTEC Holdings (TTEC) soared by 52.60%. The stock of TTEC Holdings rose following the update on a privatization proposal.

CervoMed (CRVO) increased by 36.07%, marking a two-day rally with a total gain of 48.42% over two days. CervoMed's stock surged after the company announced it would release new data regarding the impact of Neflamapimod on DLB. Researchers are set to present the clinical trial results at the 2025 AD/PD conference, which indicate that Neflamapimod can slow the clinical progression of Lewy body dementia.

Alumis (ALMS) climbed by 35.91%, achieving a four-day increase totaling 109.36%. H.C. Wainwright maintained a buy rating for Alumis, with a target price set at $15.

Cognyte Software (CGNT) rose by 21.05%, continuing its two-day upward momentum with a total gain of 27.56% over these days. The stock of Cognyte was driven by growth in its business revenue and a narrowing of losses in the fourth quarter.

The Beauty Health Company (SKIN) enjoyed a rise of 20.33%. For the fiscal year 2024, The Beauty Health Company reported a net loss of $29.10 million, an improvement of 70.90% compared to the previous year.

**Stock Performers: Bear Market**

Newsmax (NMAX) plummeted by 77.46%. The decline in Newsmax extended to 80%, currently trading at $46.52 per share, triggering a circuit breaker.

Huatai Securities (WTF) fell by 64.58%. The pressure on Huatai Securities' stock was attributed to the news of Wharton Financial completing its IPO and raising approximately $20 million. Wharton Financial exercised the overallotment option in full. This move might have redirected investor interest within the financial sector, impacting Huatai Securities' market performance.

FlashEx (FLX) dropped by 56.96%, marking a four-day consecutive decline, with a total decrease of 70.77% over these days. FlashEx, along with Dada's 2024 revenue, did not meet even two-thirds of SF Express's local services, concluding the rivalry in the third-party immediate delivery industry.

Compass Therapeutics (CMPX) decreased by 24.55%. Despite the downgrade, Leerink Partners upgraded Compass Therapeutics to a buy rating and raised the target price to $6.

Edgewise (EWTX) decreased by 22.90%, posting a four-day consecutive decline with a total drop of 33.79% over these days. The stock of Edgewise Therapeutics fell after the company released mid-stage trial data for its cardiac drug, which saw a drop of 32.9%.